Skip to main content
×
Home

Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity

  • Stefano Pallanti (a1) (a2) (a3) and Eric Hollander (a3)
Abstract

Obsessive-compulsive disorder (OCD) has been recently drawn apart from anxiety disorder by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) and clustered together with related disorders (eg, hoarding, hair pulling disorder, skin picking), which with it seems to share clinical and neurophysiological similarities. Recent literature has mainly explored brain circuitries (eg, orbitofrontal cortex, striatum), molecular pathways, and genes (eg, Hoxb8, Slitrk5, Sapap3) that represent the new target of the treatments; they also lead the development of new probes and compounds. In the therapeutic field, monotherapy with cognitive behavioral therapy (CBT) or selective serotonin reuptake inhibitors (SSRIs) is recommendable, but combination or augmentation with a dopaminergic or glutamatergic agent is often adopted. A promising therapy for OCD is represented by repetitive transcranial magnetic stimulation (rTMS), which is suitable to treat compulsivity and impulsivity depending on the protocol of stimulation and the brain circuitries targeted.

Copyright
Corresponding author
*Address for correspondence: Stefano Pallanti, University of Florence, School of Medicine, 50134, Florence (I); Ichan School of Medicine at Mount Sinai, NY 10029 (US); Albert Einstein College of Medicine and Montefiore Medical Center, NY 10461 (US). (Email: stefanopallanti@yahoo.it)
Footnotes
Hide All

The authors thank Anna Marras, PhD, for her collaboration in editing this paper.

Footnotes
References
Hide All
1. Kupfer DJ, First MB, Regier DA. A Research Agenda for DSM-V. Arlington, VA: American Psychiatric Publishing; 2008.
2. Mataix-Cols D, Boman M, Monzani B, etal. Population-based, multigenerational family clustering study of obsessive-compulsive disorder. JAMA Psychiatry. 2013; 70(7): 709717.
3. van Grootheest DS, van den Berg SM, Cath DC, Willemsen G, Boomsma DI. Marital resemblance for obsessive-compulsive, anxious and depressive symptoms in a population-based sample. Psychol Med. 2008; 38(12): 17311740.
4. Stewart SE, Yu D, Scharf JM, etal. D. Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry. 2012; 18(7): 788798.
5. Stewart SE, Mayerfeld C, Arnold PD. Meta-analysis of association between obsessive-compulsive disorder and the 3′ region of neuronal glutamate transporter gene SLC1A1. Am J Med Genet B Neuropsychiatr Genet. 2013; 162(4): 367379.
6. Abramowitz JS, Deacon B, Olatunji B, etal. Assessment of obsessive-compulsive symptom dimensions: development and evaluation of the Dimensional Obsessive-Compulsive Scale. Psychol Assess. 2010; 22: 180198.
7. Capecchi MR. Hox genes and mammalian development. Cold Spring Harb Symp Quant Biol. 1997; 62: 273281.
8. Greer JM, Capecchi MR. Hoxb8 is required for normal grooming behavior in the mouse. Neuron. 2002; 33: 2334.
9. Chen SK, Tvrdik P, Peden E, etal. Hematopoietic origin of pathological grooming in Hoxb8 mutant mice. Cell. 2010; 141(5): 775785.
10. Antony JM. Grooming and growing with microglia. Sci Signal. 2010; 3(147): jc8.
11. Wan Y, Feng G, Calakos N. Sapap3 deletion causes mGluR5-dependent silencing of AMPAR synapses. J Neurosci. 2011; 31(46): 1668516691.
12. Welch JM, Lu J, Rodriguiz RM, etal. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature. 2007; 448: 894900.
13. Wan Y, Ade KK, Caffall Z, etal. Circuit-selective striatal synaptic dysfunction in the Sapap3 knockout mouse model of obsessive-compulsive disorder. Biol Psychiatry. In press. DOI: 10.1016/j.biopsych.2013.01.008.
14. Shmelkov SV, Hormigo A, Jing D, etal. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med. 2010; 16(5): 598602.
15. Campbell KM, de Lecea L, Severynse DM, etal. OCD-like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J Neurosci. 1999; 19: 50445053.
16. Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry. 2002; 7: 617625, 524.
17. McGrath MJ, Campbell KM, Parks CR, Burton FH. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res. 2000; 877: 2330.
18. Taj M J RJ, Viswanath B, Purushottam M, etal. DRD4 gene and obsessive compulsive disorder: do symptom dimensions have specific genetic correlates? Prog Neuropsychopharmacol Biol Psychiatry. 2013; 41: 1823.
19. Cannistraro PA, Rauch SL. Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies. Psychopharmacol Bull. 2003; 37: 825.
20. Mataix-Cols D, Cullen S, Lange K, etal. Neural correlates of anxiety associated with obsessive-compulsive symptom dimensions in normal volunteers. Biol Psychiatry. 2003; 53: 482493.
21. Van den Heuvel OA, Veltman DJ, Groenewegen HJ, etal. Amygdala activity in obsessive-compulsive disorder with contamination fear: a study with oxygen-15 water positron emission tomography. Psychiatry Res. 2004; 132: 225237.
22. Simon D, Kaufmann C, Musch K, etal. Fronto-striato-limbic hyperactivation in obsessive-compulsive disorder during individually tailored symptoms provocation. Psychophysiology. 2010; 47: 728738.
23. LeDoux JE. Synaptic Self: How Our Brains Become Who We Are. New York: Viking Penguin; 2002.
24. Davis M. The role of the amygdala in fear and anxiety. Annu Rev Neurosci. 1992; 15(1): 353375.
25. Sookman D, Pinard G. Overestimation of threat and intolerance of uncertainty in obsessive compulsive disorder. In: Frost RO, Steketee G, eds. Cognitive Approaches to Obsessions and Compulsions: Theory, Assessment and Treatment. Oxford, UK: Elsevier; 2002: 6389.
26. Stein DJ. Advances in understanding the anxiety disorders: the cognitive-affective neuroscience of “false alarms”. Ann Clin Psychiatry 2006; 18: 173182.
27. Saxena S, Brody AL, Schwartz JM, etal. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry. 1998; 173(35): 2637.
28. Menzies L, Chamberlain SR, Laird AR, etal. Integrating evidence from neuroimaging and neuropsychological studies of obsessive–compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev. 2008; 32(3): 525549.
29. Depue R, Collins P. Neurobiology of the structure of personality: dopamine, facilitation of incentive motivation, and extraversion. Behav Brain Sci. 1999; 22(3): 491517.
30. Harrison BJ, Soriano-Mas C, Pujol J, etal. Altered corticostriatal functional connectivity in obsessive-compulsive disorder. Arch Gen Psychiatry. 2009; 66(11): 11891200.
31. Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2010; 35(1): 426.
32. Szechtman H, Woody E. Obsessive–compulsive disorder as a disturbance of security motivation. Psychol Rev. 2004; 111(1): 111127.
33. Endrass T, Kloft L, Kaufmann C, etal. Approach and avoidance learning in obsessive–compulsive disorder. Depress Anxiety. 2011; 28(2): 166172.
34. Beaulieu C. The basis of anisotropic water diffusion in the nervous system—a technical review. NMR Biomed. 2002; 15(7–8): 435455.
35. Sporns O. Brain networks and embodiment. In: Mesquita B, Feldman B, eds. Mind in Context. New York: Guilford Press; 2010: 4264.
36. Banks SJ, Eddy KT, Angstadt M, etal. Amygdala-frontal connectivity during emotion regulation. Soc Cogn Affect Neurosci. 2007; 2(4): 303312.
37. Kim MJ, Whalen PJ. The structural integrity of an amygdala-prefrontal pathway predicts trait anxiety. J Neurosci. 2009; 29(37): 1161411618.
38. Phillips ML, Drevets WC, Rauch SL, etal. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry. 2003; 54(5): 515528.
39. Brody AL, Saxena S, Schwartz JM, etal. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res. 1998; 84(1): 16.
40. Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive–compulsive disorder. Psychiatr Clin North Am. 2000; 23(3): 563586.
41. Menzies L, Williams GB, Chamberlain SR, etal. White matter abnormalities in patients with obsessive–compulsive disorder and their first-degree relatives. Am J Psychiatry. 2008; 165(10): 13081315.
42. Del Casale A, Kotzalidis GD, Rapinesi C, etal. Functional neuroimaging in obsessive–compulsive disorder. Neuropsychobiology. 2011; 64(2): 6185.
43. Milad MR, Rauch SL. Obsessive–compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012; 16(1): 4351.
44. Aouizerate B, Guehl D, Cuny E, etal. Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol. 2004; 72(3): 195221.
45. Maltby N, Tolin DF, Worhunsky P, etal. Dysfunctional action monitoring hyperactivates frontal-striatal circuits in obsessive-compulsive disorder: an event-related fMRI study. Neuroimage. 2005; 24(2): 495503.
46. Fitzgerald KD, Welsh RC, Gehring WJ, etal. Error-related hyperactivity of the anterior cingulate cortex in obsessive-compulsive disorder. Biol Psychiatry. 2005; 57(3): 287294.
47. Kringelbach ML. The human orbitofrontal cortex: linking reward to hedonic experience. Nat Rev Neurosci. 2005; 6(9): 691702.
48. Remijnse PL, Nielen MM, van Balkom AJ, etal. Reduced orbitofrontal-striatal activity on a reversal learning task in obsessive-compulsive disorder. Arch Gen Psychiatry. 2006; 63(11): 12251236.
49. Chamberlain SR, Menzies L, Hampshire A, etal. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science. 2008; 321(5887): 421422.
50. Figee M, Vink M, de Geus F, etal. Dysfunctional reward circuitry in obsessive-compulsive disorder. Biol Psychiatry. 2011; 69(9): 867874.
51. Rauch SL, Dougherty DD, Cosgrove GR, etal. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder. Biol Psychiatry. 2001; 50(9): 659667.
52. Hendler T, Goshen E, Tzila Zwas S, etal. Brain reactivity to specific symptom provocation indicates prospective therapeutic outcome in OCD. Psychiatry Research: Neuroimaging. 2003; 124(2): 87103.
53. Insel TR. Toward a neuroanatomy of obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49(9): 739.
54. Shanahan NA, Velez LP, Masten VL. Essential Role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Biol Psychiatry. 2011; 70(11): 10391048.
55. Melloni M, Urbistondo C, Sedeño L, etal. The extended fronto-striatal model of obsessive compulsive disorder: convergence from event-related potentials, neuropsychology and neuroimaging. Front Hum Neurosci. 2012; 6: 259.
56. Fineberg NA, Pallanti S, Reghunandanan S, Baldwin DS, Leonard BE (eds). Anxiety Disorders. Mod Trends Pharmacopsychiatry. Basel, Karger, 2003: 29: 164177.
57. Pallanti S, Hollander E, Bienstock C, etal. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002; 5(2): 181191.
58. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry. 2002; 63(9): 796.
59. Pallanti S, Grassi G. Citalopram pulse loading for severe treatment-resistant OCD: a case series of acute response, one year follow-up and tolerability. J Depress Anxiety. In press. DOI: 10.4172/2167-1044.S10-002.
60. Koran LM, Aboujaoude E, Ward H, etal. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2003; 26(1): 7983.
61. Ross S, Fallon BA, Petkova E, Feinstein S, Liebowitz MR. Long-term follow-up study of patients with refractory obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 2008; 20(4): 450457.
62. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondasetron augmentation in treatment-resistant obsessive-compulsive disorder. CNS Drugs. 2009; 23(12): 10471055.
63. Askari N, Moin M, Sanati M, etal. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2012; 26(10): 883892.
64. Hollander E, Pallanti S. Current and Experimental Therapeutics of Obsessive Compulsive Disorders, pp 1647–1664, Neuro psychopharmacology: The Fifth Generation of Progress, An Official Publication of the American College of Neuropsychopharmacology, Edited by KL Davis, D. Charney, JT Coyle and C. Nemeroff, Lippincott/Williams and Wilkins, 2002.
65. Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv. 2003; 54(8): 11111118.
66. Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2009; 70(11): 15301535.
67. Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F. Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial. CNS Spectr. 2010; 15(11): 613617.
68. Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2007; 17(6): 761767.
69. Berlin HA, Koran LM, Jenike MA, etal. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011; 72(5): 716721.
70 Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009; 29(1): 5155.
71. Abudy A, Juven-Wetzler A, Zohar J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs. 2011; 25(7): 585596.
72. Feusner JD, Kerwin L, Saxena S & Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacology bulletin. 2009; 42(1): 81.
73. Rodriguez CI, Kegeles LS, Levinson A, etal. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. In press. DOI: 10.1038/npp.2013.
74. Farrell LJ, Waters AM, Boschen MJ, etal. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of d-cycloserine augmented behavior therapy. Depress Anxiety. 2013; 30(8): 723731.
75. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2004; 65(14): 610.
76. Saxena S. Pharmacotherapy of compulsive hoarding. J Clin Psychol. 2011; 67(5): 477484.
77. Ecker W, Kupfer J, Gönner S. Incompleteness as a link between obsessive-compulsive personality traits and specific symptom dimensions of obsessive-compulsive disorder. Clin Psychol Psychother. In press. DOI: 10.1002/cpp.1842.
78. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text rev. Arlington, VA: American Psychiatric Association; 2000.
79. Grant JE, Odlaug BL, Potenza MN. Addicted to hair pulling? How an alternate model of trichotillomania may improve treatment outcome. Harv Rev Psychiatry. 2007; 15(2): 8085.
80. Lange LA, Kampov-Polevoy AB, Garbutt JC. Sweet liking and high novelty seeking: independent phenotypes associated with alcohol-related problems. Alcohol Alcohol. 2010; 45(5): 431436.
81. Schlosser S, Black DW, Blum N, Goldstein RB. The demography, phenomenology and family history of 22 persons with compulsive hair pulling. Ann Clin Psychiatry. 1994; 6(3): 147152.
82. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association.
83. Lochner C, Hemmings SM, Kinnear CJ, etal. Cluster analysis of obsessive-compulsive symptomatology: identifying obsessive-compulsive disorder subtypes. Isr J Psychiatry Relat Sci. 2008; 45(3): 164176.
84. Blum K, Braverman ER, Holder JM, etal. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs. 2000; 32(Suppl: i–iv): 1112.
85. Laine TP, Ahonen A, Rasanen P, etal. The A1 allele of the D2 dopamine receptor gene is associated with high dopamine transporter density in detoxified alcoholics. Alcohol Alcohol. 2001; 36(3): 262265.
86. Laine TP, Ahonen A, Rasanen P, etal. Dopamine transporter density and novelty seeking among alcoholics. J Addict Dis. 2001; 20(4): 9196.
87. Retz W, Rosler M, Supprian T, etal. Dopamine D3 receptor gene polymorphism and violent behavior: relation to impulsiveness and ADHD-related psychopathology. J Neural Transm. 2003; 110(5): 561572.
88. Ray LA, Bryan A, Mackillop J, etal. The dopamine D Receptor (DRD4) gene exon III polymorphism, problematic alcohol use and novelty seeking: direct and mediated genetic effects. Addict Biol. 2009; 14(2): 238244.
89. Demetrovics Z, Varga G, Szekely A, etal. Association between novelty seeking of opiate-dependent patients and the catechol-O-methyl transferase Val(158)Met polymorphism. Compr Psychiatry. 2010; 51(5): 510515.
90. Loos M, Pattij T, Janssen MC, etal. Dopaminereceptor D1/D5 gene expression in the medial prefrontal cortex predicts impulsive choice in rats. Cereb Cortex. 2010; 20(5): 10641070.
91. O'Sullivan RL, Philips KA, Keuthen NJ. Near fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine. Psychosomatics. 1999; 40(1): 7981.
92. Bloch MH, Landeros-Weisenberger A, Dombrowski P, etal. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry. 2007; 62(8): 839846.
93. Snorrason I, Belleau EL, Woods DW. How related are hair pulling disorder (trichotillomania) and skin picking disorder? A review of evidence for comorbidity, similarities and shared etiology. Clin Psychol Rev. 2012; 32(7): 618629.
94. Pallanti S, Grassi G, Sarrecchia ED, Cantisani A, Pellegrini M. Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications. Front Psychiatry. 2011; 2: 70.
95. Timpano KR, Rubenstein LM, Murphy DL. Phenomenological features and clinical impact of affective disorders in OCD: a focus on the bipolar disorder and OCD connection. Depress Anxiety. 2012; 29(3): 226233.
96. Centorrino F, Hennen J, Mallya G, etal. Clinical outcome in patients with bipolar I disorder, obsessive compulsive disorder or both. Hum Psychopharmacol. 2006; 21(3): 189193.
97. Hollander E, Buchsbaum MS, Haznedar MM, etal. FDG-PET study in pathological gamblers. 1. Lithium increases orbitofrontal, dorsolateral and cingulate metabolism. Neuropsychobiology. 2008; 58(1): 3747.
98. Dorrego MF, Canevaro L, Kuzis G, Sabe L, Starkstein SE. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder preliminary findings. J Neuropsychiatry Clin Neurosci. 2002; 14(3): 289295.
99. Koran LM, Aboujaoude E, Bullock KD, etal. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005; 66(3): 353359.
100. Amiaz R, Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol. 2008; 18(6): 455461.
101. Jaafari N, Rachid F, Rotge JY, etal. Safety and efficacy of repetitive transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: a review. World J Biol Psychiatry. 2012; 13(3): 164177.
102. Greenberg BD, George MS, Martin JD, etal. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Am J Psychiatry. 1997; 154(6): 867869.
103. Sachdev PS, McBride R, Loo CK, etal. Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. J Clin Psychiatry. 2001; 62(12): 981984.
104. Alonso P, Pujol J, Cardoner N, etal. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2001; 158(7): 11431145.
105. Kang JI, Kim CH, Namkoong K, etal. A randomized controlled study of sequentially applied repetitive transcranial magnetic stimulation in obsessive-compulsive disorder. J Clin Psychiatry. 2009; 70(12): 16451651.
106. Sarkhel S, Sinha VK, Praharaj SK. Adjunctive high-frequency right prefrontal repetitive transcranial magnetic stimulation (rTMS) was not effective in obsessive-compulsive disorder but improved secondary depression. J Anxiety Disord. 2010; 24(5): 535539.
107. Prasko J, Pasková B, Záleský R, etal. The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder: a randomized, double blind, sham controlled study. Neuro Endocrinol Lett. 2006; 27(3): 327332.
108. Sachdev PS, Loo CK, Mitchell PB, etal. Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychol Med. 2007; 37(11): 16451649.
109. Mantovani A, Lisanby SH, Pieraccini F, etal. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol. 2006; 9(1): 95100.
110. Mantovani A, Leckman JF, Grantz H, etal. Repetitive transcranial stimulation of the supplementary motor area in the treatment of Tourette syndrome: report of two cases. Clin Neurophysiol. 2007; 118(10): 23142315.
111. Mantovani A, Simpson HB, Fallon BA, etal. Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2010; 13(2): 217227.
112. Mantovani A, Westin G, Hirsch J. Functional magnetic resonance imaging guided transcranial magnetic stimulation in obsessive-compulsive disorder. Biol Psychiatry. 2010; 67(7): e39e40.
113. Alptekin K, Degermenci B, Kivircik B, etal. Tc-99 m HMPAO brain perfusion SPECT in drug-free obsessive-compulsive patients without depression. Psychiatry Res. 2001; 107(1): 5156.
114. Baxter LR, Schwartz JM, Mazziotta JC, etal. Cerebral glucose metabolic rates in non-depressed patients with obsessive-compulsive disorder. Am J Psychiatry. 1988; 145(12): 15601563.
115. Swedo SE, Schapiro MB, Grady CL, etal. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry. 1989; 46(6): 518523.
116. Ruffini C, Locatelli M, Lucca A, etal. Augmentation effect of repetitive transcranial magnetic stimulation over the orbitofrontal cortex in drug-resistant obsessive-compulsive disorder patients: a controlled investigation. Prim Care Companion J Clin Psychiatry. 2009; 11(5): 226230.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 6
Total number of PDF views: 84 *
Loading metrics...

Abstract views

Total abstract views: 375 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 24th November 2017. This data will be updated every 24 hours.